The joint summer conference between the Italian and Swiss Healthcare Licensing Groups took place on the 6th – 7th June in Milan. Over 80 attendees enjoyed the cutting-edge conference on various topics including, The current Italian and Swiss pharmaceutical markets evolution, Partnering in the field of advanced therapies, analysis of 2018 and beginning of 2019 BD&L deals with an interesting discussion about the trends. The artificial intelligence and its impact on BD&L, Business intelligence as a tool to evaluate new BD&L opportunities, Health technology and its impact on the value chain and Trends in the orphan drugs regulations and pricing and pricing of breakthrough therapies in a challenging healthcare system.Read More…
The 2019 Swiss Healthcare Licensing Group (HLG) Winter Conference focused on the topic “Capture Deal Value – When and How?”
The pharmaceutical industry is facing increasing challenges to cope with the quickly changing world economy. The requirements in healthcare are becoming ever more demanding considering the higher standard of data, financial investments and time, let alone governments` cost-containment measures getting more restrictive.
Both new and innovative molecules in the pipeline and growing access of patients to drug treatment especially in emerging markets are at the same time positive signals though. It seems that the pharmaceutical industry still finds room for creative ways to explore and implement new business models keeping pace with current changes in the healthcare environment.
Over three days, nearly 100 delegates from Switzerland, Europe, the US and Asia gathered in the Gruyère region to explore current and future innovative ways when and how to capture maximum deal value.
Conference Director, Ragip Ziyal with the active support of the entire Swiss HLG Board, gathered a global forum of high caliber speakers not only from the healthcare and consumer industry but also governmental initiatives to capture the maximum value for assets in the best manner and at the right time by (I) learning how synergies may be exploited for example during M&A transactions, (II) discussing the need for strategic access to new technologies and (III) looking at new players such as new public and public-private funding schemes as well as patient and non-profit organizations to support R&D funding.Read More…
Basel, 16th February 2018 – The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 27th Conference titled “ Reset Partnering – Step out of the Box!” With partnering deals increasing in complexity, the evolution from pharmaceuticals to solutions and the consumerization of healthcare, Business Development, and Licensing professionals need to ask themselves if the tools and approaches used are still fit for purpose in the healthcare world of 2018.
Over three days, more than 100 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and exchange on the future of partnering and to take a step out of the Box.
Conference Director, Chris Isler with the active support of the entire Swiss HLG Board, convened a global panel of leading experts from the healthcare and consumer industry addressing three main questions:
Before the start of the conference, Anthony A. Hörning, CEO of Strategic Transactions Advisor and former head of Alliance Management at Novartis led a dynamic and interactive workshop helping participants to understand “What happens after marriage – managing complex alliances”.
As an introduction, Jean-Paul Clozel, CEO of Idorsia and former CEO of Actelion, brilliantly set the stage with his thought-provoking keynote speech on his company has been acquired by Johnson & Johnson, despite not willing himself to sell it. He brought the audience to think on how the relationship and trust dimension were important to make such a transaction a success.
Francesco De Rubertis, CEO of the Medicxi Venture Fund expanded on Clozel’s thoughts with the view from the VC’s perspective and explained how entrepreneurialism and venture capital could go hand in hand. He shared his opinion as VC vs JP Clozel vision as an entrepreneur.
One of the Swiss HLG objectives is not just professional but also personal development, and hence Design Thinking Master, Rana Lonnen, Head Search and Evaluation Strategic Venture Capital at Novartis Pharma opened the day on Monday exploring how design thinking approaches can be leveraged in a partnering setting.
Six captivating presentations illustrated then what, along with the partnering process, is required to find the right deal. Alan Selby, Executive Director at Torreya Partners, shared his thoughts on when to use a broker or not. Emma Barton, Director Alliance, and Integration Management at AstraZeneca explained how Outlicensing can preserve the value of a molecule. Shigeo Taniuchi, Head of EMEA, Senior Corporate officer at Santen Pharmaceutical and Viren Mahurkar, formerly at Alcon took a look at the cultural dimension of partnerships and what to bear in mind when working with partners in Japan or China.
Tanja Dowe, CEO of the Debiopharm Innovation Fund focused on how to find the right deal with a VC fund and last but not least Vikalp Mohan, Vice President Sales and Marketing at Celonic took a look at how to partner with a Contract Development and Manufacturing Organization.
After a full day of presentations, the delegates enjoyed a short walk and typical Swiss Fondue Dinner in a barn and used the opportunity to expand their personal and professional networks.
The last day of the conference focused on how to partner beyond the molecules, starting with a case study looking at how to make more out of data by Dr. Alexandra V. Eberhard, Managing Director Europe, and Executive VP Sciences at Signals Analytics. Michael Meissner, Chief Technology Officer, at Sanofi took a look at how technology is becoming increasingly important for pharma and asked the question if pharma in this picture is the boiling frog. Ravi Sodha, Senior Director, Business Development at Actelion closed this block in sharing his perspectives on what makes deals for rare diseases different.
The closing keynote, delivered by Jon Otterstatter, CEO of the Preventice Solutions Group took the audience along the journey of building a highly successful medical technology start-up from scratch to a 500+ employee organization with prominent investors such as Merck Inc or Boston Scientific.
The Swiss HLG Board thanks the presenters and the participants for the lively discussion and interactions. Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)
Take a look at some impressions from our Winter Conference 2018.
Informative, exciting and a great opportunity to meet and exchange ideas with other Business Development Professionals.